Home › Funds › Novo Holdings A/S › CRNX

Novo Holdings A/S position in CRNX

CRINETICS PHARMACEUTICALS IN

Novo Holdings A/S reported holding 1,320,000 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$49.4M, representing 2.87% of its reported portfolio and ranking #11 among its reported holdings. Novo Holdings A/S has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.32M sh
Reported value held$49.39M
Portfolio Weight2.87%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Novo Holdings A/S's CRNX position evolved

Novo Holdings A/S first disclosed a stake in CRNX in Q3 2023 at 1,100,000 shares (US$32.7M). The position peaked in Q4 2025 at 1,625,000 shares, worth US$75.6M. Across 12 filings, Novo Holdings A/S increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 1,320,000 shares valued at US$49.4M — a reduction of -230,000 shares quarter over quarter.. Notable position changes include a 33% increase in Q1 2025.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.10M $32.71M New
Q4 2023 1.10M $39.14M Hold
Q1 2024 1.10M $51.43M Hold
Q2 2024 1.00M $44.79M Reduce
Q3 2024 1.00M $51.10M Hold
Q4 2024 960.22K $49.10M Reduce
Q1 2025 1.27M $42.76M Add
Q2 2025 1.55M $44.58M Add
Q3 2025 1.62M $67.68M Add
Q4 2025 1.62M $75.64M Hold
Q1 2026 1.55M $56.30M Reduce
Q2 2026 1.32M $49.39M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has Novo Holdings A/S held CRNX?

Novo Holdings A/S has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Novo Holdings A/S's current position in CRNX?

As of Q2 2026, Novo Holdings A/S holds 1.32M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $49.39M, representing 2.87% of its reported portfolio and ranking #11.

Has Novo Holdings A/S been buying or selling CRNX?

In the latest 13F filing (Q2 2026), Novo Holdings A/S reduced its position in CRNX. The position peaked in Q4 2025 at 1.62M shares.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.